🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

505 results for “Oral” Clear

  1. Veltassa 8.4 g powder for oral suspension, Placebo

    Istituto Gentili S.r.l.

    End Stage Kidney Disease on chronic dialysis therapy

    phase 3 small molecule active

    1 trial

  2. Venetoclax, Venetoclax, Venetoclax, Vidaza 25 mg/ml powder for suspension for injection, Placebo Venetoclax/ABT-199/Film-coated tablet Oral Use

    AbbVie Deutschland GmbH & Co. KG

    Higher-Risk Myelodysplastic Syndrome

    phase 3 small molecule active

    1 trial

  3. Vidaza 25 mg/ml powder for suspension for injection, AG-120/S95031 250mg film-coated tablet, Placebo to Match AG-120 Tablet, 250 mg, is supplied as a film-coated tablet for oral administration.

    The George Institute

    Previously Untreated Acute Myeloid Leukemia with an IDH1 Mutation

    phase 3 small molecule active

    1 trial

  4. XELJANZ 1 mg/mL oral solution, XELJANZ 1 mg/mL oral solution, XELJANZ 1 mg/mL oral solution, Tofacitinib citrate, Tofacitinib citrate, XELJANZ 1 mg/mL oral solution

    Pfizer Australia Pty Ltd

    Ulcerative Colitis (UC)

    phase 3 small molecule active

    1 trial

  5. Xyrem (sodium oxybate) oral solution

    Jazz Pharmaceuticals Ireland Limited

    Narcolepsy

    phase 3 small molecule completed

    1 trial

  6. YM087 oral

    CUMBERLAND PHARMACEUTICALS INC

    Hyponatremia

    phase 3 small molecule completed

    1 trial

  7. avoralstat

    Biocryst

    Hereditary Angioedema

    phase 3 small molecule terminated

    1 trial

  8. brivaracetam, -, -, brivaracetam, -, brivaracetam, Placebo matching < brivaracetam oral solution> and without active substance

    Lacuna Pharma Pty Ltd

    Childhood Absence Epilepsy Juvenile Absence Epilepsy

    phase 3 small molecule active

    1 trial

  9. cisplatin

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Oral Cavity

    phase 3 small molecule completed

    1 trial

  10. cognitive-behavioral withdrawal regulation strategies

    BRIGHT MINDS BIOSCIENCES INC.

    Tobacco Dependence

    phase 3 other active

    1 trial

  11. deucravacitinib, Placebo to match deucravacitinib 6mg tablets in bottle, oral use, deucravacitinib, Placebo to match deucravacitinib 2mg minitablets in sachet, oral use

    Bristol-Myers Squibb Australia Pty Ltd

    Moderate to Severe Plaque Psoriasis

    phase 3 small molecule active

    1 trial

  12. deucravacitinib, deucravacitinib, Deucravacitinib placebo 2mg film-coated tablets in sachet, oral use, deucravacitinib

    Bristol-Myers Squibb Australia Pty Ltd

    Juvenile Psoriatic Arthritis (JPsA)

    phase 3 small molecule active

    1 trial

  13. furmonertinib 240 mg oral, daily

    ArriVent BioPharma

    Metastatic Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  14. glutamine combined with thalidomide

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Mucositis Oral

    phase 3 small molecule completed

    1 trial

  15. hydrocortisone (modified release), oral tablet 20 and 5 mg

    Takeda

    Adrenal Insufficiency

    phase 3 small molecule completed

    1 trial

  16. oral estradiol 1.0 mg

    TherapeuticsMD

    Menopause

    phase 3 small molecule completed

    1 trial

  17. sapropterin

    BioMarin Pharmaceutical Australia Pty Ltd

    Behavioral Manifestations of Lesch-Nyhan Disease

    phase 3 small molecule terminated

    1 trial

  18. supersaturated calcium-phosphate

    Jazz Pharmaceuticals Ireland Limited

    Oral Complaints

    phase 3 other completed

    1 trial

  19. -, DNL593 Placebo, Sterile lyophilisate in single-dose glass vials, -, FAMOTIDINE

    Denali Therapeutics

    Frontotemporal Dementia (FTD)

    phase 2 small molecule active

    1 trial

  20. 91-day Levonorgestrel Oral Contraceptive

    Teva Pharma GmbH

    Migraine

    phase 2 small molecule completed

    1 trial

  21. 91-day Levonorgestrel Oral Contraceptive

    Teva Pharma GmbH

    Hemostasis

    phase 2 small molecule completed

    1 trial

  22. 91-day Levonorgestrel Oral Contraceptive

    Teva Pharma GmbH

    Bone Mineral Density

    phase 2 small molecule completed

    1 trial

  23. A Phase 1/2 Study of Oral LOXO-305 in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin Lymphoma (NHL)

    Wuhan Createrna Science and Technology Co., Ltd

    Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Non-Hodgkin Lymphoma (NHL)"

    phase 2 other active

    1 trial

  24. A Phase 1/2 open-label, multicenter study of oral GSK5460025 alone or in combination with other anti-cancer agents in adult participants with Mismatch Repair-deficient (dMMR) or Microsatellite Instability-High (MSI-H) solid tumors.

    GlaxoSmithKline

    Neoplasms, Colorectal

    phase 2 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources